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Abstract: Objective: In papillary thyroid carcinoma (PTC), while the role of BRAF is well established, the contribution 
of BRAF to epithelial-mesenchymal transition is not. Study design/Setting: To elucidate the relationship between 
BRAF, surrogates of epithelial-mesenchymal transition (Snail, E-cadherin) and established histopathologic prog-
nosticators in papillary thyroid carcinoma. Subjects/methods: In this IRB approved cross-sectional study, 50 cases 
of archived annotated PTC samples were retrieved and immunohistochemically stained for Snail and E-cadherin 
protein. A semi-quantitative scoring system (incorporating proportion and intensity) was utilized. Results: Snail and 
E-cadherin expression were noted in 44% and 84% of BRAF mutant and, in 29% and 95% of BRAFWT samples, 
respectively. No statistically significant correlations were noted between Snail, E-cadherin and histopathologic prog-
nosticators. However, a trend was noted between Snail expression and tumor size <5 cm (P=0.07). Statistically sig-
nificant differences between BRAF mutant and BRAFWT samples were noted in the following groups: conventional 
(68% vs. 5%) and tall cell (32% vs. 0%) histopathologic variants, extrathyroidal extension (32% vs. 5%), infiltrative 
growth pattern (80% vs. 48%), presence of desmoplasia (72% vs. 29%), psammona bodies (48% vs. 10%), and cys-
tic change (32% vs. 5%). Among follicular variant of papillary thyroid carcinoma compared to BRAF mutant samples, 
BRAFWT samples were more commonly of the encapsulated variety (52% vs. 4%), and microcarcinomas (29% vs. 
0%) (P<0.001 and =0.007, respectively). Conclusion: Our findings, supporting the utility of BRAF as a putative thera-
peutic target in PTC, suggest that the interaction between BRAF and epithelial-mesenchymal transition in papillary 
thyroid carcinoma is not through induction of the Snail/E-cadherin pathway. 
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Introduction
Papillary thyroid cancer accounts for 80% of all 
thyroid cancers, making it significantly more 
common than poorly differentiated and follicu-
lar thyroid carcinomas [1]. Over the last centu-
ry, the incidence of papillary thyroid carcinoma 
has risen over 15 fold in women and 1.2 fold in 
men [1]. Interestingly, the incidence of follicular 
and poorly differentiated thyroid carcinomas 
has remained relatively stable over this time 
[1]. In addition to an increase in primary tumors, 
there has been an increase in the incidence of 
regional and distant metastases by papillary 
thyroid carcinoma, increasing the need for 
improving our understanding of the pathogene-
sis and identifying effective, targeted treat-
ments [2].
One such molecule of interest is the BRAF pro-
tein, which has been tied to poor patient out-
come in numerous malignancies. In papillary 
thyroid carcinoma, the presence of a BRAF 
mutation has been established as a prognosti-
cator of poor clinical outcome [3-11]. The role of 
BRAF and dysregulation of the MAPK pathway 
in papillary thyroid carcinoma cell proliferation 
and survival has been well established [12]. 
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Lesser understood, but 
becoming more appar-
ent, is the contribution 
of BRAF to the epitheli-
al to mesenchymal tra- 
nsition, necessary for 
malignant carcinoma 
cells to detach from 
their primary epithelial 
site and metastasize 
[13]. One mechanism 
by which mutations to 
the BRAF protein is 
believed to contribute 
to the epithelial to mes-
enchymal transition in 
papillary thyroid carci-
noma is through upreg-
ulation of the Snail, a 
zinc finger transcrip-
tional factor, generated 
from the proto-onco-
gene SNAI1 [14]. Snail 
expression is upregu-
lated by NFκB, which 
has affinity for the 
SNAI1 promoter [15]. 
Once transcribed, Snail 
translocates to the nu- 
cleus, where it binds 
E-box, which is an E- 
cadherin promoter re- 
gion [16]. Binding to 
E-box promotes down-
regulation of E-cadh- 
erin, allowing for the 
detachment of cells fr- 
om the epithelium in a 
process known as the 
epithelial-mesenchym- 
al transition [14]. 
Given these associa-
tions and the relative 
paucity of literature on 
the interplay between 
these molecules, we 
sought to elucidate the 
relationship between 
BRAF, Snail, E-cadherin 
and established histo-
pathologic prognostica-
tors in papillary thyroid 
carcinoma. 
Table 1. Correlation of Snail with E-cadherin expression, BRAF status, 
and established histopathologic prognosticators
Histopathologic Prognosticator n  (46 total)
Snail Expression
Significance 
(p-value)Present 
(n=17)
Absent 
(n=29)
Gender
    Male 12 (26.1) 5 (29.4) 7 (24.1) 0.25a
    Female 34 (73.9) 12 (70.6) 22 (75.9)
E-Cadherin Intensity
    Present 41 (89.1) 16 (94.1) 25 (86.2) 0.64
    Not Present 5 (10.9) 1 (5.9) 4 (13.8)
BRAF Status
    Mutant 25 (54.4) 11 (64.7) 14 (48.3) 0.28
    Wild-type 21 (45.6) 6 (35.3) 15 (51.7)
Primary Tumor Size
    <5 cm 41 (89.1) 17 (100.0) 24 (82.8) 0.07b
    ≥5 cm 5 (10.9) 0 (0.0) 5 (17.24)
Conventional Variant
    Present 18 (39.1) 8 (47.1) 10 (34.5) 0.40
    Not Present 28 (60.9) 9 (52.9) 19 (65.5)
Encapsulated Follicular Variant
    Present 12 (26.1) 2 (11.8) 10 (34.5) 0.16a
    Not Present 34 (73.9) 15 (88.2) 19 (65.5)
Infiltrative Follicular Variant
    Present 14 (30.4) 4 (23.5) 10 (34.5) 0.52a
    Not Present 32 (69.6) 13 (76.5) 19 (65.5)
Papillary Microcarcinoma
    Present 6 (13.0) 2 (11.8) 4 (13.8) 1.00a
    Not Present 40 (87.0) 15 (88.2) 25 (86.2)
Tall Cell Variant
    Present 6 (13.0) 4 (23.5) 2 (6.9) 0.17a
    Not Present 40 (87.0) 13 (76.5) 27 (93.1)
Angioinvasion
    Present 6 (13.0) 3 (17.7) 3 (10.3) 0.66a
    Not Present 40 (87.0) 14 (82.3) 26 (89.7)
Multicentricity
    Present 11 (23.9) 3 (17.7) 8 (27.6) 0.5a
    Not Present 35 (76.1) 14 (82.3) 21 (72.4)
Extrathyroidal Extension
    Present 9 (19.6) 5 (29.4) 4 (13.8) 0.26a
    Not Present 37 (80.4) 12 (70.6) 25 (86.2)
Growth Pattern
    Pushing 16 (34.8) 5 (29.4) 11 (37.9) 0.56
    Infiltrative 30 (65.2) 12 (70.6) 18 (62.1)
Desmoplasia
    Present 24 (52.2) 11 (64.7) 13 (44.8) 0.19
    Not Present 22 (47.8) 6 (35.3) 16 (55.2)
Psammona Body
    Present 14 (30.4) 7 (41.2) 7 (24.1) 0.23
    Not Present 32 (69.6) 10 (58.8) 22 (75.9)
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Materials and meth-
ods
Sample selection
In this institutional re- 
view board approved 
project, annotated ca- 
ses with a diagnosis 
papillary thyroid carci-
noma (n=50) were re- 
trieved from the arc- 
hives of the Depart- 
ment of Pathology, Bo- 
ston Medical Center, 
MA, USA. Cases were 
selected such that the 
cohort contained 25 
BRAF-mutant and 25 
BRAF wild-type sam-
ples. Histopathologic 
sections of all cases 
were reviewed by 2 
board-certified pathol-
ogists (initial sign-out 
on all by a Board certi-
fied pathologist; cases 
were then re-reviewed, 
and the diagnoses con-
firmed by MM and AK). 
All patient data were 
de-identified.
DNA analyses 
DNA was extracted by 
proteinase K digestion 
and boiling. For sequ- 
encing analysis, AS- 
PCR was performed to 
detect V600E (GTG> 
GAG) and V600K (GTG> 
AAG) mutations. The 
sequencing results we- 
re analyzed with ABI 
DNA Sequencing Anal- 
ysis Software version 
6. Appropriate controls 
were included with 
each batch of PCR 
sequencing reactions.
Immunohistochemistry
Immunohistochemistry 
was performed on 4 
Tumor Associated Lymphocytes
    Present 8 (17.4) 4 (23.5) 4 (13.8) 0.44
    Not Present 38 (82.6) 13 (76.5) 25 (86.2)
Cystic Changes
    Present 9 (19.6) 5 (29.4) 4 (13.8) 0.26
    Not Present 37 (80.4) 12 (70.6) 25 (86.2)
Sclerosis
    Present 25 (54.4) 9 (52.9) 16 (55.2) 0.88
    Not Present 21 (45.6) 8 (47.1) 13 (44.8)
ap-value derived using fisher-exact. b0.5 added to all cells and fisher exact used to derive 
p-value. Note: For comparison, a chi-square derived using the more conservative Yates to 
correct for continuity yielded P=0.26 for primary tumor size.
Table 2. Correlation of E-cadherin with BRAF status and established his-
topathologic prognosticators 
Histopathologic Prognosticator n  (46 total)
Snail Expression
Significance 
(p-value)Present 
(n=41)
Absent 
(n=5)
Gender
    Male 12 (26.1) 11 (26.8) 1 (20.0) 1.00a
    Female 34 (73.9) 30 (73.2) 4 (80.0)
BRAF Status
    Mutant 25 (54.4) 21 (51.2) 4 (80.0) 0.36a
    Wild-type 21 (45.6) 20 (48.8) 1 (20.0)
Primary Tumor Size
    <5 cm 41 (89.1) 37 (90.2) 4 (80.0) 0.45a
    ≥5 cm 5 (10.9) 4 (9.8) 1 (20.0)
Conventional Variant
    Present 18 (39.1) 16 (39.0) 2 (40.0) 1.00a
    Not Present 28 (60.9) 25 (61.0) 3 (60.0)
Encapsulated Follicular Variant
     Present 12 (26.1) 12 (29.3) 0 (0.0) 0.31b
    Not Present 34 (73.9) 29 (70.7) 5 (100.0)
Infiltrative Follicular Variant
    Present 14 (30.4) 12 (29.3) 2 (40.0) 0.63a
    Not Present 32 (69.6) 29 (70.7) 3 (60.0)
Papillary Microcarcinoma
    Present 6 (13.0) 5 (12.2) 1 (20.0) 0.52a
    Not Present 40 (87.0) 36 (87.8) 4 (80.0)
Tall Cell Variant
    Present 6 (13.0) 5 (12.2) 1 (20.0) 0.52a
    Not Present 40 (87.0) 36 (87.8) 4 (80.0)
Angioinvasion
    Present 6 (13.0) 6 (14.6) 0 (0.0) Not  
Available    Not Present 40 (87.0) 35 (85.4) 5 (100.0)
Multicentricity
    Present 11 (23.9) 11 (26.8) 0 (0.0) 0.31b
    Not Present 35 (76.1) 30 (73.2) 5 (100.0)
Extrathyroidal Extension
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µm formalin-fixed, par-
affin-embedded secti- 
ons using a commer-
cially available mouse 
monoclonal antibody 
for e-cadherin (36 Ve- 
|ntana, Tucson, AZ, 
USA) at a dilution of 
1:50 and a rabbit poly-
clonal antibody for 
SNAIL1 (ab180714 Ab- 
cam, Cambridge, MA, 
USA) at a dilution of 
1:150 Target retrieval 
using Reaction Buffer 
pH 7.5 (Ventana) was 
performed at 97°C for 
30 minutes. The slides 
were treated with dual 
endogenous enzyme 
block (DAKO) before 
primary antibody stain-
ing. For E-cadherin, 
samples were incubat-
ed with the primary 
antibody for 32 min-
utes at room tempera-
ture. For Snail, samples 
were incubated with 
primary antibody over-
night at 4°C. Color de- 
velopment and contr- 
ast were achieved us- 
ing DAB and hematoxy-
lin, respectively. All 
steps were carried out 
using the Ventana Ben- 
chmark XT (Ventana). 
For all immunohisto-
chemical stains used in 
the study appropriate 
positive and negative 
controls were included 
with each run. All sta- 
ined slides were revi- 
ewed and scored by 
two authors (BM and 
MM) in a blinded fash-
ion with respect to 
each other’s scores. 
Any disagreements we- 
re reviewed together to 
achieve a consensus 
score. Internal positive 
    Present 9 (19.6) 9 (21.9) 0 (0.0) 0.32b
    Not Present 37 (80.4) 32 (78.1) 5 (100.0)
Growth Pattern
    Pushing 16 (34.8) 15 (36.6) 1 (20.0) 0.64a
    Infiltrative 30 (65.2) 26 (63.4) 4 (80.0)
Desmoplasia
    Present 24 (52.2) 22 (53.7) 2 (40.0) 0.66a
    Not Present 22 (47.8) 19 (46.3) 3 (60.0)
Psammona Body
    Present 14 (30.4) 13 (31.7) 1 (20.0) 1.00a
    Not Present 32 (69.6) 28 (68.3) 4 (80.0)
Tumor Associated Lymphocytes
    Present 8 (17.4) 8 (19.5) 0 (0.0) 0.57b
    Not Present 38 (82.6) 33 (80.5) 5 (100.0)
Cystic Changes
    Present 9 (19.6) 9 (21.9) 0 (0.0) 0.32b
    Not Present 37 (80.4) 32 (78.1) 5 (100.0)
Sclerosis
    Present 25 (54.4) 24 (58.5) 1 (20.0) 0.16
    Not Present 21 (45.6) 17 (41.5) 4 (80.0)
ap-value derived using fisher-exact. b0.5 added to all cells and fisher exact used to derive 
p-value. Note: For comparison, a chi-square derived using the more conservative Yates to 
correct for continuity yielded P=0.54 for encapsulated follicular variant, P=0.61 for multi-
centricity, P=0.79 for extrathyroidal extension, P=0.89 for tumor associated lymphocytes, 
and P=0.79 for cystic changes.
Table 3. Correlation of BRAF status with established histopathologic prog-
nosticators
Histopathologic Prognosticator n  (46 total)
BRAF Status
Significance 
(p-value)Mutant 
(n=25)
Wild-Type 
(n=21)
Gender
    Male 12 (26.1) 6 (24.0) 6 (28.6) 0.73
    Female 34 (73.9) 19 (76.0) 15 (71.4)
Primary Tumor Size
    <5 cm 41 (89.1) 24 (96.0) 17 (80.9) 0.16
    ≥5 cm 5 (10.9) 1 (4.0) 4 (19.1)
Conventional Variant
    Present 18 (39.1) 17 (68.0) 1 (4.8) <0.0001a
    Not Present 28 (60.9) 8 (32.0) 20 (95.2)
Encapsulated Follicular Variant
    Present 12 (26.1) 1 (4.0) 11 (52.4) <0.0001a
    Not Present 34 (73.9) 24 (96.0) 10 (47.6)
Infiltrative Follicular Variant
    Present 14 (30.4) 6 (24.0) 8 (38.1) 0.30
    Not Present 32 (69.6) 19 (76.0) 13 (61.9)
Papillary Microcarcinoma
    Present 6 (13.0) 0 (0.0) 6 (28.6) 0.007b
    Not Present 40 (87.0) 25 (100.0) 15 (71.4)
Tall Cell Variant
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controls were used for all stains. For e-cad-
herin, membranous staining of normal follicular 
cells was used as an internal positive control. 
For Snail, normal thyroid follicle colloid was 
used as an internal positive control.
For E-cadherin and Snail, a semi-quantitative 
scoring system was utilized with the following 
cut-offs: 1=0-10%, 2≥10-50% and 3≥50%. In 
addition, each sample was given a score of 
intensity graded as weak (1), moderate (2), and 
strong (3) as compared to internal positive con-
trols. These two scores were added up and, for 
purposes of statistical analyses, cases with a 
composite score of 4 or more were considered 
positive. For e-cadherin, statistical analysis 
was also performed using the intensity score 
algorithm. To help ensure this did not lead to a 
type-I or type-II error, the more conservative 
Yates Correction was applied, and results noted 
in the footer of Tables 1-3.
Results
Snail expression does not correlate with BRAF 
status, E-cadherin expression, and established 
histopathologic prognosticators in papillary 
thyroid carcinoma
Overall, positive Snail expression was noted in 
37% (17/46) of all samples; 44% (11/25) of 
BRAF mutant and 29% (6/21) of BRAFWT. No 
statistically significant correlations were noted 
between Snail and established histopathologic 
prognosticators; however, compared to sam-
    Present 6 (13.0) 6 (24.0) 0 (0.00) 0.02b
    Not Present 40 (87.0) 19 (76.0) 21 (100.0)
Angioinvasion
    Present 6 (13.0) 3 (12.0) 3 (14.3) 1.00a
    Not Present 40 (87.0) 22 (88.0) 18 (85.7)
Multicentricity
    Present 11 (23.9) 8 (32.0) 3 (14.3) 0.19a
    Not Present 35 (76.1) 17 (68.0) 18 (85.7)
Extrathyroidal Extension
    Present 9 (19.6) 8 (32.0) 1 (4.8) 0.03a
    Not Present 37 (80.4) 17 (68.0) 20 (95.2)
Growth Pattern
    Pushing 16 (34.8) 5 (20.0) 11 (52.4) 0.03a
     Infiltrative 30 (65.2) 20 (80.0) 10 (47.6)
Desmoplasia
    Present 24 (52.2) 18 (72.0) 6 (28.6) 0.003
    Not Present 22 (47.8) 7 (28.0) 15 (71.4)
Psammona Body
    Present 14 (30.4) 12 (48.0) 2 (9.5) 0.009a
    Not Present 32 (69.6) 13 (52.0) 19 (90.5)
Tumor Associated Lymphocytes
    Present 8 (17.4) 6 (24.0) 2 (9.5) 0.26a
    Not Present 38 (82.6) 19 (76.0) 19 (90.5)
Cystic Changes
    Present 9 (19.6) 8 (32.0) 1 (4.8) 0.03a
    Not Present 37 (80.4) 17 (68.0) 20 (95.2)
Sclerosis
    Present 25 (54.4) 12 (48.0) 13 (61.9) 0.35
    Not Present 21 (45.6) 13 (52.0) 8 (38.1)
ap-value derived using fisher-exact. b0.5 added to all cells and fisher exact used to derive 
p-value. Note: For comparison, a chi-square derived using the more conservative Yates to 
correct for continuity yielded P=0.02 for papillary microcarcinoma and P=0.07 for tall cell 
variant.
alone, as samples of- 
ten demonstrated va- 
riable staining within 
a given tumor speci- 
men.
Of note, four BRAFWT 
samples did not de- 
monstrate observable 
lesional tissue and 
could not be used for 
immunohistochemical 
analyses. 
Statistical analysis
To ascertain the clini-
cal correlates of BRAF 
mutational status, Sn- 
ail expression, and 
E-cadherin expression, 
separate (bivariate an- 
alyses) chi-square te- 
sts of independence 
were used if expected 
cell counts were great-
er than 5. However, for 
cases where cross-
tabulation resulted in 
less than cells <5, Fi- 
sher exact method 
was used, unless any 
one cell was zero. In 
those cases where 
stratification led to a 
frequency of zero, 0.5 
was added to all cells 
using a well-described 
BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma
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ples with absent snail expression, tumors dem-
onstrating Snail were more commonly less than 
5 cm (100% vs. 83%, 17/17 vs. 24/29, P=0.07). 
E-cadherin expression was positive in 94% 
(16/17) of Snail positive cases and 86% (25/29) 
of Snail negative cases, indicating the absence 
of a statistically significant association. Results 
are summarized in Table 1, Figure 1. 
E-cadherin expression does not correlate with 
BRAF status and established histopathologic 
prognosticators in papillary thyroid carcinoma 
Overall, E-cadherin expression, based off of 
cumulative score (proportion of cells stained 
and intensity), yielded positivity in all cases. 
Due to this, we used the intensity score alone 
Figure 1. Representative examples of cases from study with positive immunohistochemical staining for Snail and 
E-cadherin (Case 2, A-C) and negative immunohistochemical staining for Snail and positive immunohistochemical 
staining for E-cadherin (Case 27, D-F). A = H&E; B = Positive immunohistochemical staining for Snail; C = Positive 
immunohistochemical staining for E-cadherin. D = H&E; E = Negative immunohistochemical staining for Snail; F = 
Positive immunohistochemical for E-cadherin.
BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma
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Table 4. Studies evaluating the BRAF/Snail/E-cadherin pathway in papillary thyroid carcinoma
Study Samples BRAF SNAIL E-cadherin Conclusions
Walgenbach et al. 
(1998) [21]
Papillary thyroid carcinoma biop-
sies (n=78)
BRAF not 
studied
Snail not 
studied
IHC Decreased e-cadherin expression correlated with locoregional tumor recurrence, lymph node metasta-
sis, distant metastasis, and shorter survival
Hardy et al. (2007) 
[17]
Thyroid carcinoma cell lines and 
papillary thyroid carcinoma biop-
sies (n=32)
BRAF not 
studied
RT-PCR,  
Western blot-
ting, and IHC
RT-PCR 1. SNAIL is upregulated and e-cadherin downregulation in thyroid carcinoma cell lines
2. SNAIL expression enhances papillary thyroid carcinoma development in mice
3. SNAIL protein is expressed in patient samples
Erdem et al. (2011) 
[42]
Papillary thyroid carcinoma biop-
sies (n=79)
BRAF not 
studied
Snail not 
studied
IHC Decreased e-cadherin expression is correlated with gender 
Guerra et al. (2012) 
[43]
Papillary thyroid carcinoma biop-
sies (n=168)
DNA sequencing Snail not 
studied
E-cadherin 
not studied
BRAF mutation correlated with age, tumor volume, and disease recurrence
Liu et al. (2012) 
[22]
Papillary thyroid carcinoma biop-
sies (n=81)
BRAF not 
studied
Snail not 
studied
IHC Decreased e-cadherin expression correlated with increased age, invasion, lymph node metastasis and 
stage
Baquero et al. 
(2013) [18]
Thyroid cancer cell lines Transfection 
with BRAFV600E 
DNA
Western blot RT-PCR 1. BRAF mutation induces SNAIL upregulation via ERK1/2 dependent mechanism
2. SNAIL downregulated E-cadherin
3. This pathway promotes thyroid cancer cell migration and invasion
Jung et al. (2015) 
[23]
Papillary thyroid carcinoma (n=60) 
and anaplastic thyroid carcinoma 
(n=17) biopsies
BRAF not 
studied
IHC IHC 1. E-cadherin expression was retained in all papillary thyroid carcinomas 
2. Snail expression was more common in anaplastic thyroid carcinoma than papillary thyroid carcinoma
3. Epithelial-mesenchymal transition and cancer stem cell markers associated with more aggressive 
forms of thyroid carcinoma
Mitchell et al. 2016 
(current study)
Papillary thyroid carcinoma biop-
sies (n=50)
Direct DNA 
sequencing
IHC IHC 1. The interaction between BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma  
is not through induction of the Snail/E-cadherin pathway
2. BRAF may be of utility as putative therapeutic target in papillary thyroid carcinoma
BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma
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to further stratify cases. Using this approach, 
89% (41/46) of cases demonstrated positive 
E-cadherin expression; 84% (21/25) of BRAF 
mutant and 95% (20/21) of BRAFWT cases. 
E-cadherin expression did not correlate with 
established histopathologic prognosticators of 
poor clinical outcome. Results are summarized 
in Table 2.
BRAF mutation is associated with multiple 
established histopathologic prognosticators of 
poor clinical outcome
Statistically significant differences between 
BRAF mutant and BRAFWT samples were noted 
in the following: conventional (68% vs. 5%, 
17/25 vs. 1/21) and tall cell (24% vs. 0%, 6/25 
vs. 0/21) variants, extrathyroidal extension 
(32% vs. 5%, 8/25 vs. 1/21), infiltrative growth 
pattern (80% vs. 48%, 20/25 vs. 10/21), des-
moplasia (72% vs. 29%, 18/25 vs. 6/21), 
psammona bodies (48% vs. 10%, 12/25 vs. 
2/21), and cystic change (32% vs. 5%, 8/25 vs. 
1/21). Of note, compared to BRAF mutant sam-
ples, those that were BRAFWT were more com-
monly of the encapsulated follicular (4% vs. 
52%, 1/25 vs. 11/21, P<0.001) and microcar-
cinoma (0% vs. 29%, 0/25 vs. 6/21, P=0.007) 
variants. Results are summarized in Table 3.
Discussion
In murine papillary thyroid carcinoma cells, it 
was demonstrated that downregulation of Snail 
resulted in upregulation of E-cadherin and inhi-
bition of the malignant cell’s capacity for migra-
tion and invasion [17]. Building on this, Baquero 
et al., demonstrated that upregulation of Snail 
in thyroid carcinoma cells lines led to downreg-
ulation of E-cadherin expression [18]. We found 
E-cadherin to be expressed in almost all of our 
samples, irrespective of Snail expression, a 
finding at odds with most previously published 
observations (Table 4). This discordance may 
be attributed to differences in samples studied 
(i.e. cell lines vs. patient samples) and quantifi-
cation methodology (i.e. PCR vs. immunohisto-
chemistry). To better stratify our scoring, we 
then looked at intensity of E-cadherin expres-
sion alone; however almost 90% of our samples 
still retained E-cadherin expression. Taken 
together, our findings argue that epithelial-mes-
enchymal transition in papillary thyroid carci-
noma is not regulated via loss of E-cadherin 
expression. Further in support of this, over 94% 
of samples expressing Snail also demonstrated 
expression of E-cadherin. These findings argue 
that progression of papillary thyroid carcinoma, 
a variant with a less aggressive phenotype, is 
not mediated by upregulation of the transcrip-
tional repressor Snail with a concomitant 
decrease of its target E-cadherin. Given the role 
of these molecules in poorly differentiated vari-
ants of thyroid carcinoma, it is possible that 
other molecules in the tumor microenviron-
ment may contribute to the in vitro observa-
tions of the enhanced role of Snail in E-cadherin 
in epithelial-mesenchymal transition. Further 
in support of this, a recent study by Ma et al. 
demonstrates that dedifferentiation, in the 
form of enhanced expression of stem cell genes 
(i.e. Oct4, Rex1, CD15, and Sox2), associates 
with epithelial-mesenchymal transition pro-
gression in thyroid carcinoma cell lines [19]. 
Specifically, in vitro analysis of papillary thyroid 
carcinoma cell lines revealed decreased 
expression of the epithelial marker E-cadherin 
and increased expression of epithelial-mesen-
chymal transition regulators including Snail, 
Slug, TGF-β1/3, and the mesenchymal marker 
vimentin, with concordant acquisition of a can-
cer stem cell-like phenotype [19]. Further stud-
ies evaluating cancer stem cells in papillary 
thyroid carcinoma samples may help in clarify-
ing the relationship between tumor microenvi-
ronment and epithelial-mesenchymal tran- 
sition.
In 2011, Liu et al. noted a dichotomy in 
E-cadherin expression at the tumor front as 
compared with the tumor focus [20]. In the 
same study it was noted that loss of E-cadherin 
expression at the invasive front of papillary thy-
roid carcinoma correlated with the develop-
ment of lymph node metastasis [20]. We also 
noted that a loss of E-cadherin expression con-
fined to the invasive tumor front (n=10). In addi-
tion, we noted that these areas of E-cadherin 
repression at the invasive front retained expres-
sion of Snail. 
The utility of E-cadherin expression as a prog-
nosticator of clinical outcome in papillary thy-
roid carcinoma is uncertain. Two previous stud-
ies correlated loss of E-cadherin with meta- 
stasis and shorter survival [21, 22]. However, 
more recent studies, our own as well as that of 
Jung et al., demonstrating ubiquitous expres-
sion of E-cadherin in papillary thyroid carcino-
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ma argue against the prognostic utility of 
E-cadherin [23]. Potential causes of this discor-
dance may be attributable to differences in 
methodology including dilution (1:100 vs. 1:50), 
temperature for primary antibody incubation 
(48°C vs. 4°C) as well as well as differences in 
the epitopes targeted by the primary antibody. 
In regards to Snail, while expression also did 
not appear to be of utility as a prognosticator in 
our cohort, a trend was noted between Snail 
expression and tumors <5 cm. The precise sig-
nificance of this is unclear. Additional studies 
such as corroboration of this in a larger sample 
size is indicated.  
Several studies have demonstrated the role of 
BRAF mutant in the progression and metasta-
sis of select variants of thyroid carcinoma [18, 
24-30]. A 2005 study demonstrated that onco-
genic BRAF alters the expression of select 
genes associated with cell adhesion (i.e. 
RUNX2, MMPs), migration (i.e. chemokines) 
and proliferation (i.e. Akt) in cell lines derived 
from normal rat follicular cells in vitro [24]. 
Follow-up studies showed that BRAFV600E 
regulates the expression of matrix metallopro-
teinases (MMPs)-required for metastatic inva-
sion-through an NFκB-dependent pathway in 
normal rat and human follicular cells in vitro as 
well as in patient samples [25-27]. Other mole-
cules that have been associated with BRAF 
mutation and epithelial-mesenchymal transi-
tion in papillary thyroid carcinoma are the mol-
ecules Smad, thrombospondin-1, and TGFβ 
[28-30]. In 2013, Baquero et al. demonstrated 
that thyroid cancer cells expressing mutant 
BRAF showed upregulated Snail expression 
and downregulation of E-cadherin in vitro [18]. 
Furthermore, in vitro administration of a BRAF 
inhibitor resulted in a loss of migratory and 
invasive potential, arguing that this pathway 
was relevant in the epithelial to mesenchymal 
transition observed during the progression of 
select thyroid carcinomas [18]. Interestingly, 
the three cell lines used in this study were of 
follicular, undifferentiated, or anaplastic thyroid 
carcinoma lineage, rendering the role of BRAF 
mutation in the less aggressive, albeit more 
common, papillary thyroid carcinoma unstud-
ied. Interestingly, our findings indicate that the 
Snail/E-cadherin pathway is not dysregulated 
by the presence of a BRAF mutation in papillary 
thyroid carcinoma. Considering that BRAF 
mutation is associated with poor prognosis in 
papillary thyroid carcinoma, we hypothesize 
that the oncogenic protein may be influencing 
tumorigenesis through an alternative pathway, 
or may require additional “hits” to the tumor 
microenvironment prior to alterations in the 
Snail/E-cadherin cascade [11, 31]. This inclu- 
des MAPK proteins downstream of BRAF (i.e. 
MEK/ERK), NFκB, the chemokine receptor 
CXCR4, all of which have been shown to influ-
ence Snail, and subsequently E-cadherin 
expression in non-thyroid malignancies [26, 32, 
33]. 
Our findings, like those from previous studies, 
are in support of the utility of BRAF status as a 
prognosticator of patient outcome [3-11]. In our 
cohort, we found that the mutant BRAF geno-
type was associated with the tall cell histopath-
ologic variant, presence of extrathyroidal exten-
sion, infiltrative growth pattern, desmoplasia, 
and psammona bodies, all of which have been 
shown to be associated with a more aggressive 
tumor phenotype [34-37]. These findings sup-
port the utility of BRAF inhibitors, such as 
Vemurafenib, in the treatment of papillary thy-
roid carcinoma [38-40]. We also found that cys-
tic change was also associated with BRAF 
mutation, although the prognostic utility of this 
feature is not fully established [41]. 
In conclusion, our findings indicate that the 
BRAF mutation does not appear to induce epi-
thelial to mesenchymal transformation in papil-
lary thyroid carcinoma via the Snail/E-cadherin 
pathway. Snail and E-cadherin expression do 
not appear to be of utility, as prognosticator of 
poor clinical outcome. The association between 
BRAF and poor prognosticators further sup-
ports the utility of BRAF as a putative therapeu-
tic target in papillary thyroid carcinoma. 
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